McKesson Corporation (M1CK34) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of McKesson Corporation BRL 67.24, price BRL 72.31, upside -7.0%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range R$14.39 – R$81.70 · fair‑value band R$41.81 – R$87.41 · the R$72.31 price screens above the R$67.24 fair value. Dashed = 300-day average. As of Sep 29, 2026.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
Show more
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Stock analysis
McKesson Corporation (M1CK34) currently trades at R$72.31, while our model-based Fair Value estimate is R$67.24, so the stock looks roughly fairly valued today (gap 7.5%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$79.49 per share, and 13 of the 21 models we run sit above the R$72.31 price.
Bear case: the Economic Profit group reads lowest at R$39.36, and 8 of the 21 models stay below the price. Evidence for this calculation is high.
Scenario range: R$41.81 (bear) to R$87.41 (bull), the price of R$72.31 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
McKesson Corporation reported revenue of $403B in FY2026 versus $264B in FY2022, a compound +11.2%/yr. Reported net income was $4.8B in FY2026, compounding +43.8%/yr from FY2022.
Key figures
Market cap R$499B (≈ $95.6B) · P/E ratio 21.5 · P/S ratio 0.25 · EPS (TTM) R$49.68 · Dividend yield 0.3% · Net margin 1.2% · Return on assets (EBIT) 6.1% · Operating margin 2.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at −7%, M1CK34 screens richer than that median.
Fair Value models
Bear R$41.81Fair Value R$67.24Bull R$87.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (R$23.70 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+40.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+40.5%
Dividend (yield on the price)0.3%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 2%
2026 sits 52% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "McKesson Corporation Fair Value". https://www.fairvalue-calculator.com/stock/M1CK34
Frequently asked questions
Is McKesson Corporation (M1CK34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$67.24 versus a price of R$72.31, about −7% upside (fairly valued).
What is the fair value of M1CK34?
Our model-based fair value for McKesson Corporation is R$67.24 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$72.31.
What is the quality score of M1CK34?
McKesson Corporation has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for McKesson Corporation (M1CK34)?
Our model-based price target is the fair value of R$67.24 (as of Sep 29, 2026) from 21 valuation models. Cautious scenario R$41.81, optimistic scenario R$87.41. It is a calculation from audited fundamentals, not an analyst target.
What is the McKesson Corporation stock forecast for 2026?
Our models put fair value at R$67.24, about −7% upside versus a price of R$72.31 (fairly valued). Cautious scenario R$41.81, optimistic scenario R$87.41. The calculation is refreshed regularly with new filings.
What is the revenue of McKesson Corporation (M1CK34)?
McKesson Corporation reported trailing-twelve-month revenue of about $403B (latest available figure, as of Sep 29, 2026).
Does McKesson Corporation pay a dividend?
McKesson Corporation currently shows a dividend yield of about 0.31% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of McKesson Corporation (M1CK34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For McKesson Corporation it is R$67.24 per share (as of Sep 29, 2026), against a price of R$72.31. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is McKesson Corporation stock overvalued or undervalued in 2026?
As of Sep 29, 2026, M1CK34 trades above its calculated fair value: price R$72.31, fair value R$67.24, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of M1CK34?
No. The price is what the market pays today (R$72.31); the fair value is what the company's own numbers justify (R$67.24). For McKesson Corporation the two are R$5.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is McKesson Corporation worth?
The market values McKesson Corporation at about R$499B (market capitalisation, as of Sep 29, 2026). Per share that is R$72.31; our models calculate a fair value of R$67.24 per share.
What do the bullish and bearish scenarios say about M1CK34?
Our models span a range for McKesson Corporation: cautious scenario R$41.81, base R$67.24, optimistic R$87.41 per share (as of Sep 29, 2026, price R$72.31). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is M1CK34 from its 52-week high?
McKesson Corporation trades at R$72.31, about 11% below its 52-week high of R$81.70 and 29% above the low of R$55.85 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$67.24 is for.
Which stocks are comparable to McKesson Corporation?
From the same area (Healthcare) we also value Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, Shanghai Pharmaceuticals Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is McKesson Corporation stock attractive at the current price?
The data as of Sep 29, 2026: price R$72.31, calculated fair value R$67.24 (−7%), Quality Score 66/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of M1CK34 calculated?
We run McKesson Corporation through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$67.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. McKesson Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of McKesson Corporation (M1CK34)?
The closing price on Oct 2, 2026 was R$72.31. Our model-based fair value is R$67.24, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with McKesson Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (R$41.81 to R$87.41) leaves room in how you read the outcome.
Key figures of McKesson Corporation
How large is the market capitalisation of McKesson Corporation (M1CK34)?
The market capitalisation of McKesson Corporation is R$499B (≈ $95.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of McKesson Corporation (M1CK34)?
The price-to-earnings ratio of McKesson Corporation is 21.5 (as of Jul 17, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of McKesson Corporation (M1CK34)?
The price-to-sales ratio of McKesson Corporation is 0.25 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of McKesson Corporation (M1CK34)?
Earnings per share at McKesson Corporation are R$49.68 (price ÷ EPS = P/E 21.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of McKesson Corporation (M1CK34)?
The dividend yield of McKesson Corporation is 0.3% (payout 0.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of McKesson Corporation (M1CK34)?
The net margin of McKesson Corporation is 1.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of McKesson Corporation (M1CK34)?
On an EBIT basis the return on assets of McKesson Corporation is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of McKesson Corporation (M1CK34)?
The operating margin of McKesson Corporation is 2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at McKesson Corporation (M1CK34)?
Revenue at McKesson Corporation is growing +6.0% versus a year earlier (3y avg +13.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at McKesson Corporation (M1CK34)?
Earnings per share at McKesson Corporation are growing +37.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does McKesson Corporation (M1CK34) generate?
The free cash flow of McKesson Corporation is $5.4B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does McKesson Corporation (M1CK34) carry?
The net debt of McKesson Corporation is $2.6B (fiscal year 2026, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
